Thirty-day Treatment Continuation After Audio-only Buprenorphine Telehealth Initiation
- PMID: 36102540
- DOI: 10.1097/ADM.0000000000001077
Thirty-day Treatment Continuation After Audio-only Buprenorphine Telehealth Initiation
Abstract
Objectives: Before the coronavirus disease 2019 pandemic, federal law required in-person evaluation before buprenorphine initiation. Regulatory changes during the pandemic allow for buprenorphine initiation by audio-only or audiovisual telehealth. Little is known about treatment engagement after buprenorphine initiation conducted via audio-only telehealth.
Methods: A retrospective cohort study of 94 individuals who received initial treatment through an audio-only encounter between April 2020 and February 2021 was performed. Participant demographics, substance use history, withdrawal symptoms, 30-day treatment engagement, and adverse outcomes were determined by an electronic chart and REDcap database review. Subsequent buprenorphine prescriptions filled within 30 days of the initial encounter were tracked through the Rhode Island Prescription Drug Monitoring Program.
Results: Buprenorphine was prescribed for 94 individuals. Most (92 of 94 [97.9%]) filled their prescription within 30 days. Most had previously taken buprenorphine, including prescribed (42 of 92 [45.7%]) and nonprescribed (58 of 92 [63.0%]). Two thirds were in opioid withdrawal at the time of the call (61 of 92 [66.3%]) with a mean Subjective Opioid Withdrawal Scale of 26.8 (range, 4-57). Four individuals experienced precipitated withdrawal (4 of 94 [4.3%]), and 2 reported persistent withdrawal at their follow-up visit (2 of 94 [2.1%]). More than 70% filled a subsequent prescription for buprenorphine within 30 days of the end of their hotline prescription (65 of 92 [70.7%]), on average of 5.88 days (range, 0-28) after completion of their telehealth prescription.
Conclusions: Expanding telehealth-delivered buprenorphine care has the potential to address treatment gaps and facilitate delivery of on-demand services during peak motivation. This evaluation of audio-only buprenorphine initiation found high rates of unobserved buprenorphine initiation and treatment continuation with low rates of complications.
Copyright © 2022 American Society of Addiction Medicine.
Conflict of interest statement
The authors report no conflicts of interest.
References
-
- Centers for Disease Control and Prevention. Provisional drug overdose death counts. National Center for Health Statistics. Available at: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm . Accessed April 16, 2022.
-
- Santo T Jr., Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiat . 2021;78(9):979–993.
-
- Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med . 2011;5(1):21–27.
-
- Volkow ND. Stigma and the toll of addiction. N Engl J Med . 2020;382:1289–1290.
-
- Grimm C. Office of the Inspector General: Geographic Disparities Affect Access to Buprenorphine Services for Opioid Use Disorder. 2020. OEI-12-17-00240. Available at: https://oig.hhs.gov/oei/reports/oei-12-17-00240.pdf . Accessed April 16, 2022.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
